

The Gastrointestinal Tract and Long COVID

Saurabh Mehandru MD

Professor and Associate Chief of Research

Division of Gastroenterology

Icahn School of Medicine at Mount Sinai, New York



**Mount
Sinai**

Disclosures

1. Grant funding from:

1. Takeda Pharma
2. Genentech Pharma

2. Speaking engagements for:


1. Takeda Pharma
2. Genentech Pharma
3. Morphic
4. Glaxo Smith Kline

NO RELATION TO THE PRESENT TOPIC

Outline of the presentation

- ▶ Rationale for studying the GI tract in COVID
- ▶ Acute infection studies
- ▶ Persistence of SARS-CoV-2 in the GI tract
- ▶ Ongoing and planned work

Prevailing hypothesis regarding the pathogenesis of Long COVID



Rationale for investigating the GI tract in COVID-19

- ▶ Patients demonstrate GI symptoms
- ▶ GI infection was demonstrated in SARS-CoV epidemic of 2003
- ▶ Multiple members of the Coronaviridae family can infect enterocytes
- ▶ Publications regarding infection of human enteroids by SARS-CoV-2 in vitro



Infection of bat and human intestinal organoids by SARS-CoV-2


Jie Zhou^{1,2,6}✉, Cun Li^{2,6}, Xiaojuan Liu^{2,6}, Man Chun Chiu^{1,2}, Xiaoyu Zhao^{1,2}, Dong Wang², Yuxuan Wei², Andrew Lee^{1,2}, Anna Jinxia Zhang^{1,2}, Hin Chu^{1,2}, Jian-Piao Cai², Cyril Chik-Yan Yip², Ivy Hau-Yee Chan³, Kenneth Kak-Yuen Wong^{1,3}, Owen Tak-Yin Tsang⁴, Kwok-Hung Chan^{1,2}, Jasper Fuk-Woo Chan^{1,2,5}, Kelvin Kai-Wang To^{1,2,5}, Honglin Chen^{1,2} and Kwok Yung Yuen^{1,2,5}✉



Duodenum

ACE-2 is physiologically expressed on the small intestinal brush border


Suarez-farinas, Tokuyama, Gastroenterology 2020



n=14 (14 NV, 0 IBD)

ACE2
EPCAM
DAPI



Acute COVID-19 cohort summary and sample description



*Case #19 was biopsied at the GEJ, duodenum and ileum sites

*Case #2 (pediatric) had the transplanted small intestine and native duodenum biopsied

#One Control only had blood available






GE junction

Duodenum









Terminal Ileum


Left colon

ACE2 EPCAM DAPI




Nucleocapsid EPCAM DAPI






Mild evidence of intestinal inflammation based on cellular infiltrates





Patient 8 (duodenum)



Patient 9 (duodenum)

Intestinal biopsies during and immediate post acute phase show unexpected attenuation of inflammatory pathways



■ CONTROLS


■ COVID-19



Summary

- SARS-CoV-2 viral particles can be detected by IF and EM in intestinal tissue of patients with concurrent (or recent) COVID-19
- The majority of COVID-19 patients examined in the acute to post acute stage show patchy and mild signs of intestinal inflammation (neutrophils, architectural distortion and/ or intraepithelial lymphocytes)
- Intestinal biopsies during and immediately post acute COVID-19 showed an unexpected decrease myeloid cells and inflammatory pathways when compared to normal volunteer-derived biopsies

Intestines default to inducing tolerance against luminal antigens




Speculation: Lack of sterilizing immunity in the gut during initial infection may allow for viral persistence


Persistence of SARS-CoV-2 in the GI tract

- Initially 14 subjects (now > 50) with prior diagnosis of COVID-19
- Studied at 4 months post infection (range, 2.8-5.7 months) (now upto 2 year)
- Immunostaining for NP antigens
- PCR and sequence verification of SARS-CoV-2
- Insitu hybridization
- Cellular subset examination

SARS-CoV-2 persists in the GI tract well beyond the resolution of clinical disease




Significant increase in plasma cells and tissue resident memory T cells




Unpublished

Plasma cells (CD19-CD38+CD27+)



Tissue Resident memory cells (CD103+CD69+)



- Normal Volunteer
- Post-COVID IF positive
- Post-COVID IF negative

Summary of persistent immune cell abnormalities in the GI tract

- Persistence of viral proteins can be seen in our cohort for more than one year
- Innate and adaptive immune cell abnormalities persist in the intestinal mucosa of COVID-recovered individuals
- Abnormalities may reflect viral persistence or prolonged immune dysregulation in the intestines
- We have not been able to culture live virus out of the intestines

Key Take Away Points

- Long COVID is a heterogeneous disorder with multiple organ system manifestations, dominated by neuropsychiatric and systemic symptoms
- Prevailing hypotheses include immune dysregulation, autoimmunity and persistence of viral reservoirs
- Intestinal viral reservoirs could potentially be associated with attenuated inflammation and less than 'sterilizing protection' during the acute phase of illness

Where are we going with this?

Investigating the role of the GI tract in the pathogenesis of Long COVID



Patient cohort



Spatial transcriptomics



Project coordination


Balvi Foundation Funded

Proposed studies

Group 1: Long COVID patients with GI symptoms (n=20)

Group 2: Long COVID patients without GI symptoms (n=10)

Group 3: Post-COVID but no long COVID (n=10)




© MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED.



Transcriptomic profiling with scRNA seq
Advanced microscopy
Flow cytometry
Serological studies
Viral culture
Spatial transcriptomics
Spatial metatranscriptomics
Biobanking of tissue

Acknowledgements



Mehandru Laboratory

Saurabh Mehandru
Hadar Meringer
Alexandra Livanos
Divya Jha
Francesca Cossarini
Minami Tokuyama
Michael Tankelevich

Bakel Lab

Ana Silvia Gonzalez-Reiche

Garcia-Sastre Lab

Teresa Aydillo-Gomez

NIH Grant: NIH/NIDDK 1R01 123749S1

Patients and participants @ Mount Sinai Hospital

HIMC

Brian Lee
Adeeb Rahman
Miriam Merad

Gastroenterologists

Nikhil Kumta
Satish Nagula
Ari Grinspan

Francesca Petralia

Rockefeller University

Humanitas University, Milan, Italy

California Institute of Technology

Weill Cornell College of Medicine



**Mount
Sinai**

Mehandru Laboratory



Saurabh.Mehandru@mssm.edu